Key result
Inhibition of GATA4 multimerization suppresses cardiomyocyte hypertrophy, highlighting a potential therapeutic target in heart failure.
Answers are grounded in this paper and cite their sources.
Demonstrates that GATA4 multimerization drives hypertrophic gene transcription in cardiomyocytes, suggesting a novel therapeutic target for heart failure.
The activation of the GATA-binding factor 4 (GATA4) transcription factor induces cardiac hypertrophy and heart failure. The multimerization of transcription factors often plays an important role in the regulation of transcriptional activity. Here, we report that the GATA4 transcription factor forms a homomultimer and that residues 308-326 of GATA4 are necessary for its multimerization. The acetylation of GATA4 by the transcriptional co-activator p300 induces the multimerization of GATA4 and activates its DNA binding activity. In addition, we found that the suppression of GATA4 multimerization did not reduce its acetylation, but repressed GATA4/p300-induced gene transcription. Furthermore, the inhibition of GATA4 multimerization suppressed phenylephrine (PE)-induced hypertrophic response in cardiomyocytes. This study demonstrates that the multimerization of GATA4 during the p300-induced acetylation of GATA4 activates the transcription of hypertrophic response genes, which leads to cardiomyocyte hypertrophy. Therefore, the inhibition of GATA4 homomultimerization could serve as a potential therapeutic strategy for the development of novel drugs against heart failure.
No takes yet. Share an insight, caveat, or question.
Shimizu et al. (2022) studied Cardiac hypertrophy. Inhibition of GATA4 multimerization was evaluated on Phenylephrine (PE)-induced hypertrophic response in cardiomyocytes. Inhibition of GATA4 multimerization suppressed phenylephrine-induced hypertrophic response in cardiomyocytes, representing a potential therapeutic strategy against heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: